Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
Miehlke S, Schlag C, Lucendo AJ, Biedermann L, Vaquero CS, Schmoecker C, Hayat J, Hruz P, Ciriza de Los Rios C, Bredenoord AJ, Vieth M, Schoepfer A, Attwood S, Mueller R, Burrack S, Greinwald R, Straumann A; International EOS-2 Study Group.
Miehlke S, et al. Among authors: vaquero cs.
United European Gastroenterol J. 2022 Apr;10(3):330-343. doi: 10.1002/ueg2.12220.
United European Gastroenterol J. 2022.
PMID: 35412032
Free PMC article.